Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

(2013) M. Gnant et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

(2013) Shinzaburo Noguchi et al.   Breast Cancer

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

(2012) Roberto Iacovelli et al.   ACTA ONCOLOGICA

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions

(2012) C. Villarreal-Garza et al.   ANNALS OF ONCOLOGY

1st International consensus guidelines for advanced breast cancer (ABC 1)

(2012) F. Cardoso et al.   BREAST

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?

(2012) Palma Fedele et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Reversing Hormone Resistance: Have We Found the Golden Key?

(2012) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Blocking both driver and escape pathways improves outcomes

(2012) Mothaffar F. Rimawi et al.   Nature Reviews Clinical Oncology

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus

(2011) Monique P. Curran   PEDIATRIC DRUGS

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

(2010) Terry OʼReilly et al.   ANTI-CANCER DRUGS

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

The tumor microenvironment and its contribution to tumor evolution toward metastasis

(2008) Girieca Lorusso et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

(2007) Ahmad Awada et al.   EUROPEAN JOURNAL OF CANCER